Long-Term Quality of Life in Patients With Metastatic Melanoma Treated With Checkpoint Inhibitors
Sponsor: Memorial Sloan Kettering Cancer Center
This observational or N/A phase trial investigates Metastatic Melanoma and is currently completed. Memorial Sloan Kettering Cancer Center leads this study, which shows 11 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
Status: Active Not Recruiting → Completed
-
Mar 2020 — Jan 2021 [monthly]
Active Not Recruiting
-
Mar 2019 — Mar 2020 [monthly]
Active Not Recruiting
▶ Show 6 earlier versions
-
Nov 2018 — Mar 2019 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Aug 2018 — Nov 2018 [monthly]
Recruiting
-
Jun 2018 — Aug 2018 [monthly]
Recruiting
-
Apr 2018 — Jun 2018 [monthly]
Recruiting
Phase: NA → None
-
Feb 2018 — Apr 2018 [monthly]
Recruiting NA
-
Nov 2017 — Feb 2018 [monthly]
Recruiting NA
First recorded
Oct 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Memorial Sloan Kettering Cancer Center
For direct contact, visit the study record on ClinicalTrials.gov .